Comparing the effectiveness of Upadacitinib and TNF inhibitors for rheumatoid arthritis in Germany

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to compare the retention rates of Upadacitinib (UPA) versus tumor necrosis factor inhibitors (TNFi) in adult patients with moderate to severe active rheumatoid arthritis (RA) in Germany. Approximately 678 participants will be enrolled across 80 sites, with recruitment lasting around 24 months and participation lasting up to 24 months. The study will assess the effectiveness of these treatments as prescribed by physicians according to local standards of care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Current or Past participants with a confirmed diagnosis of moderate to severe active RA upon judgement of the treating physician.
* Physician decision on participant treatment with Upadacitinib (UPA) or tumor necrosis factor inhibitor (TNFi) must have been reached prior to and independently of recruitment in the study
* UPA or TNFi prescribed in accordance with the applicable approved label and local regulatory and reimbursement policies

Exclusion Criteria:

* Participation in a clinical trial with an investigational drug (within a minimum of 30 days or 5 half-lives of the investigational drug \[whichever is longer\] prior to baseline)
* Prior treatment with Upadacitinib
* Prior treatment with the same tumor necrosis factor inhibitor as the one prescribed for this study

Where it's running

• Gemeinschaftspraxis Innere Medizin/Rheumatologie /ID# 278584
  Freiburg im Breisgau, Baden-Wurttemberg, Germany Recruiting
• Rheumapraxis Heidelberg /ID# 276475
  Heidelberg, Baden-Wurttemberg, Germany Recruiting
• Rheumapraxis Haas Tubingen /ID# 275536
  Tübingen, Baden-Wurttemberg, Germany Recruiting
• Rheumapraxis Ulm Dr. med. Nadia Rinaldi /ID# 276293
  Ulm, Baden-Wurttemberg, Germany Recruiting
• Dr. Med. Thomas Marycz /ID# 274646
  Amberg, Bavaria, Germany Recruiting
• Rheumapraxis Am Webereck /ID# 274412
  Augsburg, Bavaria, Germany Recruiting

+25 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Medical Information Germany
• Email: medinfo.germany@abbvie.com
• Phone: 49 611 1720 1520

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Safety and drug level study of multiple doses of upadacitinib, tofacitinib, and baricitinib in healthy adults

  This early-phase study tests how different doses of upadacitinib, tofacitinib, and baricitinib behave in healthy adults to understand safety and how the drugs act in the body.

  Recruiting Phase 1 AbbVie · Grayslake, Illinois · NCT07843693

• Upadacitinib for Severe Alopecia Areata in Children

  This study tests whether upadacitinib can safely help children with severe alopecia areata grow back hair, compared with placebo.

  Recruiting at 14 sites Phase 3 AbbVie · Los Angeles, California and 13 other locations · NCT07772492

• Upadacitinib for Eosinophilic Esophagitis in adults not responding to standard therapy

  This study tests whether upadacitinib, taken with topical corticosteroids, can reduce disease activity in adults with eosinophilic esophagitis who still have symptoms.

  Recruiting Phase 2 University of North Carolina, Chapel Hill · Chapel Hill, North Carolina and 1 other locations · NCT07588568

• Upadacitinib versus infliximab for second-line treatment of acute severe ulcerative colitis

  This trial will see if upadacitinib or infliximab works better to induce remission in adults with acute severe ulcerative colitis who need second-line therapy.

  Recruiting at 4 sites Phase 4 Xijing Hospital of Digestive Diseases · Ankang, Shaanxi and 3 other locations · NCT07550673

• Upadacitinib versus corticosteroids for first-line treatment of acute severe ulcerative colitis

  This test will see if upadacitinib works as well as corticosteroids to induce remission in adults with acute severe ulcerative colitis.

  Recruiting at 4 sites Phase 4 Xijing Hospital of Digestive Diseases · Ankang, Shaanxi and 3 other locations · NCT07546097

• TNFi plus low-dose upadacitinib versus TNFi dose intensification for Crohn's disease with suboptimal response

  This trial tests whether adding low-dose upadacitinib to a standard TNF blocker helps adults with moderate-to-severe Crohn's disease who haven't responded well to standard-dose infliximab or adalimumab, compared with increasing the TNFi dose.

  Recruiting Phase 4 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT07510191

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.